Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (Q44165611)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 March 2013

Language	Label	Description	Also known as
English	Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial	scientific article published on 18 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (English)

1 reference

Europe PubMed Central

30 November 2017

phase IV clinical trial

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Paul Emery

0 references

Ronald van Vollenhoven

3

object named as

Ronald van Vollenhoven

1 reference

Europe PubMed Central

30 November 2017

object named as

Karel Pavelka

6

0 references

1

object named as

Cem Gabay

1 reference

Europe PubMed Central

30 November 2017

Christof Specker

0 references

Arthur Kavanaugh

11

object named as

Arthur Kavanaugh

1 reference

Europe PubMed Central

30 November 2017

author name string

Ara Dikranian

4

1 reference

Europe PubMed Central

30 November 2017

Rieke Alten

5

1 reference

Europe PubMed Central

30 November 2017

Micki Klearman

7

1 reference

Europe PubMed Central

30 November 2017

David Musselman

8

1 reference

Europe PubMed Central

30 November 2017

Sunil Agarwal

9

1 reference

Europe PubMed Central

30 November 2017

Jennifer Green

10

1 reference

Europe PubMed Central

30 November 2017

ADACTA Study Investigators

12

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

18 March 2013

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

381

1 reference

Europe PubMed Central

30 November 2017

9877

1 reference

Europe PubMed Central

30 November 2017

1541-1550

1 reference

Europe PubMed Central

30 November 2017

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine. A prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized antihuman IL-6 receptor antibody, tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960250-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)60250-0

1 reference

Europe PubMed Central

30 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44165611&oldid=2107340970"